Available products

Download PDF Product list

Product Family Name Dosage Form Dosage Strength Development Status Dossier Readiness ATC Group 4B Zone Stability* Available Territory
ABACAVIR SULFATE + LAMIVUDINE Film-coated tablet 600 + 300 mg ready registered Antiinfectives for systemic use not available Global
ABIRATERONE ACETATE Film-coated tablet 500 mg ongoing registered Antineoplastic and immunomodulating agents available Global
ACETYLSALICYLIC ACID Tablet 100 mg ongoing Q4 2021 Nervous system not available Global
AMLODIPINE Tablet 5mg, 10mg ready dossier registered Cardiovascular system available Global
AMLODIPINE BESILATE + CANDESARTAN CILEXETIL Tablet 5 mg + 8 mg; 10 mg + 16 mg ready dossier registered Cardiovascular system available EU countries
AMLODIPINE BESILATE + INDAPAMIDE + PERINDOPRIL ERBUMINE Tablet 5 mg + 16 mg; 5 mg + 32 mg; 10 mg + 32 mg ready dossier registered Cardiovascular system available Global
AMLODIPINE BESILATE + INDAPAMIDE + PERINDOPRIL ERBUMINE Tablet 5 + 1.25 + 4 mg; 10 + 1.25 + 4 mg; 5 + 2.5 + 8 mg; 10 + 2.5 + 8 mg ready dossier registered Cardiovascular system available Global, except CEE & IT
AMLODIPINE BESILATE + PERINDOPRIL ERBUMINE Film-coated tablet 5 + 4 mg; 10 + 4 mg; 5 + 8 mg; 10 + 8 mg ready dossier registered Cardiovascular system available Global
AMLODIPINE BESILATE + VALSARTAN Film-coated tablet 5 + 80 mg; 5 + 160 mg; 10 + 160 mg ongoing registered Blood and blood forming organs available EU countries
APIXABAN Film-coated tablet 2.5 mg, 5 mg ongoing Q4 2021 Blood and blood forming organs available EU countries
APREMILAST Film-coated tablet 10 mg, 20 mg, 30 mg ongoing Q4 2021 Dermatological drugs available Global
ATAZANAVIR SULFATE Capsule, hard 150 mg, 200 mg, 300 mg ready dossier registered Antiinfectives for systemic use available Global
ATORVASTATIN CALCIUM Film-coated tablet 10 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg ready dossier registered Cardiovascular system available Global
BISOPROLOL FUMARATE Tablet 1.25 mg; 2.5 mg; 3.75 mg; 5 mg; 7.5 mg; 10 mg ready dossier registered Cardiovascular system not available Global
CLOPIDOGREL BISULPHATE Film-coated tablet 75 mg ongoing Q1 2022 Blood and blood forming organs available Global
DAPAGLIFLOZIN amorphous Film-coated tablet 5 mg, 10 mg ongoing Q3 2022 Alimentary tract and metabolisma not available EU countries
DAPAGLIFLOZIN crystalline Film-coated tablet 5 mg, 10 mg ongoing Q3 2024 Alimentary tract and metabolisma not available EU countries
DEFERASIROX Film-coated tablet 90 mg, 180mg and 360mg ready dossier registered Various ATC structures not available Global
DULOXETINE HYDROCHLORIDE Capsule, gastro-resistant, hard 30 mg, 60 mg ready dossier registered Nervous system available Global
DULOXETINE HYDROCHLORIDE Capsule, gastro-resistant, hard 20 mg, 40 mg ready dossier registered Urology available EU countries
EDOXABAN Film-coated tablet 15 mg, 30 mg, 60 mg ongoing Q3 2023 Nervous system available Global
EMTRICITABINE + RILPIVIRINE +TENOFOVIR ALAFENAMIDE Film-coated tablet 200 + 25 + 25 mg 200 + 27.5 + 28 mg ongoing Q2 2024 Antivirotic on demand Global
EMTRICITABINE + TENOFOVIR ALAFENAMIDE Film-coated tablet 200 + 10 mg 200 + 25 mg ongoing Q1 2024 Antivirotic on demand Global
EMPAGLIFLOZIN Film-coated tablet 10 mg, 25 mg ongoing Q1 2024 Alimentary tract and metabolisma on demand Global
ETORICOXIB Film-coated tablet 30 mg, 60 mg, 90 mg, 120 mg ready dossier registered Blood and blood forming organs on demand EU countries
FINGOLIMOD Capsule, hard 0,5 mg ready filed in EU Multiple Sclerosis not available EU countries
HYDROCHLOROTHIAZIDE + LOSARTAN POTASSIUM Film-coated tablet 12.5 + 50 mg; 12.5 + 100 mg; 25 + 100 mg ready dossier registered Cardiovascular system not available Global
HYDROCHLOROTHIAZIDE + TELMISARTAN Tablet 12.5 + 40 mg; 12.5 + 80 mg; 25 + 80 mg ready dossier registered Cardiovascular system available Global
IBANDRONATE SODIUM MONOHYDRATE Film-coated tablet 150 mg ready dossier registered Musculoskeletal system available EU countries
IBUPROFEN Film-coated tablet 200 mg, 400 mg, 600 mg, 800 mg ready dossier registered Musculoskeletal system not available EU countries
ILOPROST Nebuliser solution 20 mcg/ml ready dossier registered Blood and blood forming organs not available Global, except UK, DE, IT, RU
IVABRADINE HYDROCHLORIDE Film-coated tablet 5 mg; 7.5 mg ready dossier registered Nervous system available Global
LACOSAMIDE Film-coated tablet 50 mg, 100 mg, 150 mg, 200 mg ready dossier registered Nervous system available Global
LEVETIRACETAM Film-coated tablet 250 mg, 500 mg, 750 mg, 1000 mg ready dossier registered Nervous system available EU countries
LINAGLIPTIN Film-coated tablet 5 mg ongoing filed in UE Alimentary tract and metabolisma available EU countries
LINAGLIPTIN + METFORMIN Tablet 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg ongoing Q4 2022 Alimentary tract and metabolisma not available Global
METAMIZOLE NA Tablet 500mg ready filed in EU Nervous system not available Global
METAMIZOLE NA Injection 500 mg/ml (2 ml) ongoing Q4 2021 Nervous system not available Global
METFORMIN + SITAGLIPTIN Film-coated tablet 1000 mg/50 mg, 850 mg/50 mg ongoing Q3 2022 Alimentary tract and metabolisma available Global
METFORMIN HYDROCHLORIDE Film-coated tablet 500 mg, 850 mg, 1000mg ready dossier registered Alimentary tract and metabolisma available Global
NILOTINIB Capsule 150 mg, 200 mg; (50 mg pending) ongoing Q1 2022 Antineoplastic and immunomodulating agents not available non-EU countries
NOREPINEPHRINE Injection 1 mg/ml ongoing Q3 2021 various not available Global, except CZ, SK, FR, PL, UK, SE, DK, NO
PARACETAMOL Tablet 500mg, 1000mg ongoing Q1 2021 Nervous system not available Global
PERINDOPRIL ARGININE Film-coated tablet 2.5 mg, 5 mg, 10 mg ongoing Q1 2021 Cardiovascular system not available Global
PRASUGREL HYDROCHLORIDE Film-coated tablet 5 mg, 10 mg ongoing Q4 2021 Blood and blood forming organs not available Global
RAMIPRIL Tablet 1.25 mg, 2.5 mg, 5 mg, 10 mg ongoing Q3 2022 Cardiovascular system not available Global
RIVAROXABAN Film-coated tablet 2.5 mg; 10 mg, 15 mg, 20 mg ongoing registered Blood and blood forming organs (Venous thromboembolism) available EU countries
RIVAROXABAN Capsule, hard 2.5 mg; 10 mg, 15 mg, 20 mg ongoing registered Blood and blood forming organs (Venous thromboembolism) available EU countries
ROSUVASTATIN CALCIUM Film-coated tablet 5 mg; 10 mg, 20 mg, 40 mg ready filed in UE Cardiovascular system available Global
SACUBITRIL + VALSARTAN Film-coated tablet 25 + 25 mg, 50 + 50 mg, 100 + 100 mg ongoing Q4 2022 Cardiovascular system on demand EU countries
SERTRALINE Tablet 25 mg ready registered Nervous system not available Global except UK, SE, DK
SITAGLIPTIN PHOSPHATE Film-coated tablet 25 mg, 50 mg, 100 mg ongoing Q4 2021 Alimentary tract and metabolisma on demande Global
SITAGLIPTIN PHOSPHATE + METFORMIN Film-coated tablet 50 + 500 mg, 50 + 850 mg ongoing Q2 2022 Alimentary tract and metabolisma on demande Global
SOLIFENACIN SUCCINATE Film-coated tablet 5 mg, 10 mg ready dossier registered Genitourinary system and reproductive hormones available
TAMSULOSIN HYDROCHLORIDE Modified-release capsule, hard 0.4 mg ready dossier registered Genitourinary system and reproductive hormones available EU countries
TICAGRELOR Film-coated tablet 60 mg, 90 mg ongoing Q1 2021 Blood and blood forming organs not available Global
TORASEMIDE Tablet 2.5, 5, 10, 20, 50, 100, 200 mg ongoing Q1 2022 Cardiovascular system on demand Global
VARDENAFIL HYDROCHLORIDE TRIHYDRATE Film-coated tablet 5 mg, 10 mg, 20 mg ready dossier registered Genitourinary system and reproductive hormones available EU countries
VILDAGLIPTIN Tablet 50 mg ready dossier registered Alimentary tract and metabolisma available EU countries

*4B Zone stability can be fulfilled upon request if not available at the moment

Dosage Form: Film-coated tablet
Dosage Strength: 600 + 300 mg
Development Status: ready
Dossier Readiness: registered
ATC Group: Antineoplastic and immunomodulating agents
4B Zone Stability* not available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 500 mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Antineoplastic and immunomodulating agents
4B Zone Stability* available
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 100 mg
Development Status: ongoing
Dossier Readiness: Q4 2021
ATC Group: Nervous system
4B Zone Stability* not available
4B Zone Stability* Global

Dosage Form: Tablet
Dosage Strength: 5mg, 10mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* available
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 5 mg + 8 mg, 10 mg + 16 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Tablet
Dosage Strength: 5 mg + 16 mg,   5 mg + 32 mg, 10 mg + 32 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* available
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 6.934 + 1.25 + 4 mg; 13.868 + 1.25 + 4 mg; 6.934 + 2.5 + 8 mg; 13.868 + 2.5 + 8 mg (5+1.25+4; 10+1.25+4; 5+2.5+8; 10+2.5+8 mg)
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* available
Available Territory Global, except CEE & IT

Dosage Form: Tablet
Dosage Strength: 6.934 + 4 mg; 13.868 + 4 mg; 6.934 + 8 mg; 13.868 + 8 mg ( 5/4; 10/4; 5/8; 10/8 mg)
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 6.935 + 80 mg; 6.935 + 160 mg; 13.870 + 160 mg (5/80; 5/160; 10/160 mg)
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Film-coated tablet
Dosage Strength: 2.5 mg, 5 mg
Development Status: on going
Dossier Readiness: Q4 2021
ATC Group: Blood and blood forming organs
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Film-coated tablet
Dosage Strength: 10 mg, 20 mg, 30 mg
Development Status: ongoing
Dossier Readiness: Q4 2021
ATC Group: Dermatological drugs
4B Zone Stability* available
Available Territory Global

Dosage Form: Capsule, hard
Dosage Strength: 170.86 mg; 227.81 mg; 341.71 mg (150 mg, 200 mg, 300 mg)
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Antiinfectives for systemic use
4B Zone Stability* available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 10 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* available
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 1.25 mg; 2.5 mg; 3.75 mg; 5 mg; 7.5 mg; 10 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 75 mg
Development Status: ongoing
Dossier Readiness: Q1 2022
ATC Group: Blood and blood forming organs
4B Zone Stability* available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg, 10 mg
Development Status: ongoing
Dossier Readiness: Q3 2022
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* not available
Available Territory EU countries

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg, 10 mg
Development Status: ongoing
Dossier Readiness: Q3 2024
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* not available
Available Territory EU countries

Dosage Form: Film-coated tablet
Dosage Strength: 90 mg, 180mg and 360mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Various ATC structures
4B Zone Stability* not available
Available Territory Global

Dosage Form: Capsule, gastro-resistant, hard
Dosage Strength: 30mg, 60 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Nervous system
4B Zone Stability* available
Available Territory Global

Dosage Form: Capsule, gastro-resistant, hard
Dosage Strength: 20 mg, 40 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Urology
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Film-coated tablet
Dosage Strength: 15 mg, 30 mg, 60 mg
Development Status: ongoing
Dossier Readiness: Q3 2023
ATC Group: Blood and blood forming organs
4B Zone Stability* on demand
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 10 mg, 25 mg
Development Status: ongoing
Dossier Readiness: Q1 2024
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* on demand
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 200 + 25 + 25 mg
200 + 27.5 + 28 mg
Development Status: ongoing
Dossier Readiness: Q2 2024
ATC Group: Antivirotic
4B Zone Stability* on demand
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 200 + 10 mg
200 + 25 mg
Development Status: ongoing
Dossier Readiness: Q1 2024
ATC Group: Antivirotic
4B Zone Stability* on demand
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 30 mg, 60 mg, 90 mg, 120 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Musculoskeletal system
4B Zone Stability* not available
Available Territory EU countries

Dosage Form: Capsule, hard
Dosage Strength: 0.5 mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Multiple Sclerosis
4B Zone Stability* not available
Available Territory EU countries

Dosage Form: Film-coated tablet
Dosage Strength: 12.5 + 50 mg; 12.5 + 100 mg; 25 + 100 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 12.5 + 40 mg; 12.5 + 80 mg; 25 + 80 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* available
Available Territory Global
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 168.75 mg (150 mg)
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Musculoskeletal system
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Film-coated tablet
Dosage Strength: 200 mg, 400 mg, 600 mg, 800 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Musculoskeletal system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Nebuliser solution
Dosage Strength: 20 mcg/ml
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Blood and blood forming organs
4B Zone Stability* not available
Available Territory Global except UK, DE, IT, RU

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg; 7.5 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Cardiovascular system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 50 mg, 100 mg, 150 mg, 200 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Nervous system
4B Zone Stability* available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 250 mg, 500 mg, 750 mg, 1000 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Nervous system
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg
Development Status: ongoing
Dossier Readiness: filed in EU
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Tablet
Dosage Strength: 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg
Development Status: ongoing
Dossier Readiness: Q4 2022
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* not available
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 500mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Nervous system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Injection
Dosage Strength: 500 mg/ml (2 ml)
Development Status: ongoing
Dossier Readiness: Q4 2021
ATC Group: Nervous system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 1000 mg/50 mg, 850 mg/50 mg
Development Status: ongoing
Dossier Readiness: Q3 2022
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 500 mg, 850 mg, 1000mg
Development Status: ready
Dossier Readiness:  filed in EU
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* available
Available Territory Global

Dosage Form: Capsule
Dosage Strength: 150 mg, 200 mg; (50 mg pending)
Development Status: ongoing
Dossier Readiness: Q1 2022
ATC Group: Antineoplastic and immunomodulating agents
4B Zone Stability* not available
Available Territory non-EU countries

Dosage Form: Injection
Dosage Strength: 1 mg/ml
Development Status: ongoing
Dossier Readiness: Q3 2021
ATC Group: various
4B Zone Stability* not available
Available Territory Global except CZ, SK, FR, PL, UK, SE, DK, NO

Dosage Form: Tablet
Dosage Strength: 500mg, 1000mg
Development Status: ongoing
Dossier Readiness: Q1 2021
ATC Group: Nervous system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 2.5 mg, 5 mg, 10 mg
Development Status: ongoing
Dossier Readiness: Q1 2021
ATC Group: Cardiovascular system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5,490 mg; 10,980 mg (5 mg, 10 mg)
Development Status: ongoing
Dossier Readiness: Q4 2021
ATC Group: Blood and blood forming organs
4B Zone Stability* available
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 1.25 mg, 2.5 mg, 5 mg, 10 mg
Development Status: ongoing
Dossier Readiness: Q3 2022
ATC Group: Cardiovascular system
4B Zone Stability* not available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 2.5 mg; 10 mg, 15 mg, 20 mg
Development Status: ongoing
Dossier Readiness: registered
ATC Group: Blood and blood forming organs (Venous thromboembolism)
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Capsule, hard
Dosage Strength: 2.5 mg; 10 mg, 15 mg, 20 mg
Development Status: ongoing
Dossier Readiness: registered
ATC Group: Blood and blood forming organs (Venous thromboembolism)
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg; 10 mg, 15mg, 20 mg, 30mg, 40 mg
Development Status: ready
Dossier Readiness: filed in EU
ATC Group: Cardiovascular system
4B Zone Stability* available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 25 + 25 mg, 50 + 50 mg, 100 + 100 mg
Development Status: ongoing
Dossier Readiness: Q4 2022
ATC Group: Cardiovascular system
4B Zone Stability* on demand
Available Territory EU countries

Dosage Form: Tablet
Dosage Strength: 25 mg
Development Status: ongoing
Dossier Readiness: registered
ATC Group: Nervous system
4B Zone Stability* not available
Available Territory Global 
except UK, SE, DK

Dosage Form: Film-coated tablet
Dosage Strength: 25 mg, 50 mg, 100 mg
Development Status: ongoing
Dossier Readiness: Q4 2021
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* on demand
4B Zone Stability* on demand
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 50 + 500 mg, 50 + 850 mg
Development Status: ongoing
Dossier Readiness: Q2 2022
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* on demand
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5 mg, 10 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Genitourinary system and reproductive hormones
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Modified-release capsule, hard
Dosage Strength: 0.4 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Genitourinary system and reproductive hormones
4B Zone Stability* available
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 60 mg, 90 mg
Development Status: ongoing
Dossier Readiness: Q1 2021
ATC Group: Blood and blood forming organs
4B Zone Stability* not available
Available Territory Global

Dosage Form: Tablet
Dosage Strength: 2.5, 5, 10, 20, 50, 100, 200 mg
Development Status: ongoing
Dossier Readiness: Q1 2022
ATC Group: Cardiovascular system
4B Zone Stability* on demand
Available Territory Global

Dosage Form: Film-coated tablet
Dosage Strength: 5.926 mg; 11.852 mg; 23.704 mg (5 mg, 10 mg, 20 mg)
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Genitourinary system and reproductive hormones
4B Zone Stability* available
Available Territory EU countries

Dosage Form: Tablet
Dosage Strength: 50 mg
Development Status: ready
Dossier Readiness: dossier registered
ATC Group: Alimentary tract and metabolisma
4B Zone Stability* available
Available Territory EU countries

Available MA

Product Family Name Dosage Form Dosage Strength Development Status Dossier Readiness
ABACAVIR + LAMIVUDINE Film-coated tablet 600 mg + 300 mg EU DPC Poland

Available MA

Dosage Form: Film-coated tablet
Dosage Strength: 600 mg + 300 mg
Development Status: EU DPC
Dossier Readiness: Poland

Dosage Form: Orodispersible tablet
Dosage Strength: 5 mg, 10 mg, 20 mg
Development Status: EU DPC
Dossier Readiness: Czech Republic

Available API

Product Name API
ARTICAINE HYDROCHLORIDE API
GLIBENCLAMIDE API
PENTOXIFYLLINE API
AGOMELATINE API


DISCLAIMER:

Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.